Novantrone for MS 5-year phase IV RENEW study results reported
Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis (RENEW) was a 5-year, phase IV study in which the safety of Mitoxantrone was monitored in a patient cohort from the United States (US). The objective of the study was to evaluate the long-term safety profile of Mitoxantrone in patients with secondary progressive multiple sclerosis (SPMS), progressive relapsing multiple sclerosis (PRMS), and worsening relapsing-remitting multiple sclerosis (RRMS)..... Read More - http://www.ms-uk.org/index.cfm/novantrone
Novantrone for MS 5-year phase IV RENEW study results report
Novantrone for MS 5-year phase IV RENEW study results report
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1425 Views
-
Last post by NHE
-
- 0 Replies
- 1314 Views
-
Last post by frodo
-
- 0 Replies
- 1727 Views
-
Last post by NHE
-
- 1 Replies
- 3167 Views
-
Last post by Tif
-
- 2 Replies
- 4372 Views
-
Last post by DIM
-
- 0 Replies
- 2512 Views
-
Last post by NHE
-
- 1 Replies
- 1244 Views
-
Last post by Scott1
-
- 1 Replies
- 1942 Views
-
Last post by frodo
-
- 0 Replies
- 2273 Views
-
Last post by DIM